Tuisku-Tuulia Koivula1, Anni Tuulasvaara2, Iivo Hetemäki2, Satu Marjo Mäkelä3, Jukka Mustonen4, Tarja Sironen5, Antti Vaheri5, T Petteri Arstila2. 1. Department of Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland; Research Programs Unit, Immunobiology, Haartman Institute, University of Helsinki, Helsinki, Finland. Electronic address: tuisku.koivula@helsinki.fi. 2. Department of Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland; Research Programs Unit, Immunobiology, Haartman Institute, University of Helsinki, Helsinki, Finland. 3. Department of Medicine, University of Tampere School of Medicine, Tampere, Finland; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland. 4. Department of Medicine, University of Tampere School of Medicine, Tampere, Finland. 5. Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Abstract
OBJECTIVES: Hantaviruses are an important group of emerging zoonotic pathogens, with significant mortality rates. Immunopathology is thought to be important in hantaviral disease, but the balance between protective and harmful responses is unknown. We studied Puumala hantavirus (PUUV) infection, which causes hemorrhagic fever with renal syndrome (HFRS) with a generally mild but highly variable clinical course. METHODS: Clinical data and blood samples were collected from 24 patients with acute PUUV infection, and analyzed by flow cytometry and quantitative PCR. RESULTS: The patients had a significantly increased frequency of CD4(+) and CD8(+) cells expressing the cell cycle marker Ki-67, but the magnitude of the effector T cell response did not correlate with disease severity. The frequency of FOXP3(+) regulatory T (Treg) cells expressing Ki-67 was also increased, and likewise did not correlate with disease outcome. In contrast, the level of FOXP3 expression, a surrogate of the suppressive phenotype, had a strong positive correlation with disease severity. This correlation was also found in samples taken 6-12 months after the HFRS. CONCLUSIONS: The best predictor of a severe disease course in HFRS was the FOXP3(+) Treg cell response, suggesting that the role of Treg cells in acute human hantaviral infections may be deleterious.
OBJECTIVES: Hantaviruses are an important group of emerging zoonotic pathogens, with significant mortality rates. Immunopathology is thought to be important in hantaviral disease, but the balance between protective and harmful responses is unknown. We studied Puumala hantavirus (PUUV) infection, which causes hemorrhagic fever with renal syndrome (HFRS) with a generally mild but highly variable clinical course. METHODS: Clinical data and blood samples were collected from 24 patients with acute PUUV infection, and analyzed by flow cytometry and quantitative PCR. RESULTS: The patients had a significantly increased frequency of CD4(+) and CD8(+) cells expressing the cell cycle marker Ki-67, but the magnitude of the effector T cell response did not correlate with disease severity. The frequency of FOXP3(+) regulatory T (Treg) cells expressing Ki-67 was also increased, and likewise did not correlate with disease outcome. In contrast, the level of FOXP3 expression, a surrogate of the suppressive phenotype, had a strong positive correlation with disease severity. This correlation was also found in samples taken 6-12 months after the HFRS. CONCLUSIONS: The best predictor of a severe disease course in HFRS was the FOXP3(+) Treg cell response, suggesting that the role of Treg cells in acute humanhantaviral infections may be deleterious.
Authors: Anna Papa; Antti Vaheri; James W LeDuc; Detlev H Krüger; Tatjana Avšič-Županc; Jiro Arikawa; Jin-Won Song; Alemka Markotić; Jan Clement; Mifang Liang; Dexin Li; Liudmila N Yashina; Colleen B Jonsson; Connie S Schmaljohn Journal: Antiviral Res Date: 2016-08-17 Impact factor: 5.970
Authors: Svetlana F Khaiboullina; Silvana Levis; Sergey P Morzunov; Ekaterina V Martynova; Vladimir A Anokhin; Oleg A Gusev; Stephen C St Jeor; Vincent C Lombardi; Albert A Rizvanov Journal: Front Immunol Date: 2017-05-18 Impact factor: 7.561
Authors: J Klingström; A Smed-Sörensen; K T Maleki; C Solà-Riera; C Ahlm; N K Björkström; H G Ljunggren Journal: J Intern Med Date: 2019-02-17 Impact factor: 8.989